Royalty Report: Drugs, Cancer, Therapeutic – Collection: 260428


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 260428

License Grant
The Italian Licensor grants an exclusive, even as to Licensor, right and license under Licensors right in and to the Technology to research, develop, make, have made, use, offer for sale, sell, have sold, distribute, import, and export the Licensed Compound and/or the Products in the Licensed Field in the Territory.
License Property
Licensor owns the rights to a compound known as IDN 5109 and has acquired and developed certain know-how concerning such compound.

The terms Licensed Compound or API shall mean the compound known as ION 5109, also known as Ortataxel, and any polymorph, analog or derivative thereof.

Field of Use
The term Licensed Field shall mean all uses, human or otherwise, including all therapeutic, prophylactic, palliative and diagnostic uses.  The specific compound is used in treating cancer in humans.

Ortataxel is a drug used in chemotherapy.

IPSCIO Record ID: 222534

License Grant
Licensor grants an exclusive license, or sublicense, as the case may be, under the Licensor Patent Rights and Know-how, in each case with the right to grant sublicenses, to research, develop, make, have made, use, import, export, market, offer for sale, sell and have sold, Licensed Product in the Territory within the applicable Field.
License Property
The Compounds means SCH 619734 (Rolapitant) and SCH 900978.

The Licensed Product means any product comprising, incorporating or containing any Compound, or an alternate form of any Compound, including, but not limited to, a pharmaceutically acceptable salt, polymorph, crystal form, prodrug, or solvate of any Compound to the extent such alternate form is claimed in the Licensor Patent Rights.

Rolapitant, a Phase III-ready, oncology supportive-care product candidate, is a potent and selective neurokinin-1 (NK-1) receptor antagonist with an extended plasma half-life that has the potential to improve the management of nausea and vomiting experienced by cancer patients undergoing treatment with emetogenic chemotherapy. Phase II clinical testing of rolapitant for the prevention of nausea and vomiting in cancer patients treated with highly emetogenic chemotherapy demonstrated promising five-day activity following the administration of a single dose.

Field of Use
The Field means with respect to SCH 619734 (Rolapitant) all therapeutic, prophylactic, palliative and diagnostic uses in humans, and means, with respect to SCH 900978, treatment of nausea or vomiting of any cause; treatment of disease or treatment of symptoms or side effects of disease in oncology indications; treatment of side effects of oncology treatments or therapies; and (iv) any other supportive care indications in oncology.

IPSCIO Record ID: 238988

License Grant
Licensor grants a sole and exclusive license to the Swiss Licensee, with a right to sublicense, under the Licensor Patent Rights and Licensor Know-How to develop, use, sell, offer for sale, import and/or export Compounds and Licensed Products in the Territory and in the Field, and make and have made Compounds and Licensed Products in the Territory for such development, use, sale, offering for sale, importation and/or exportation.
License Property
Licensor owns or possesses certain patent rights, know-how and regulatory filings with respect to epothilones, including epothilone D, and believes that epothilone D has the potential to become an anti-cancer agent.

Compound means any epothilone, or analog, derivative, prodrug or metabolite of an epothilone, including but not limited to epothilone A, B, C and D, a compound that is analog, derivative, prodrug or metabolite of an epothilone, including but not limited to epothilone A, B, C and D, and any compound identified in scientific journals or patent publications as an epothilon, analog, derivative, prodrug or metabolite.

Back-Up Compound means a Compound other than epothilone D that may be suitable for development for use in the Field, until and unless it comes to be included in a Replacement Licensed Product.

Licensed Product means any product containing a Compound, the Commercialization of which would either use Licensor Know-How, including without limitation because the product was researched or developed using Licensor Know-How or but for this Agreement, infringe a Valid Claim.

Field of Use
Field means the treatment, palliation, and/or prevention of cancer.  Potential applications include breast cancer and non-hodgkin lymphoma.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.